EP4746884A2 - Inhibiteurs de la g9a/glp et méthodes d'utilisation - Google Patents

Inhibiteurs de la g9a/glp et méthodes d'utilisation

Info

Publication number
EP4746884A2
EP4746884A2 EP24846288.9A EP24846288A EP4746884A2 EP 4746884 A2 EP4746884 A2 EP 4746884A2 EP 24846288 A EP24846288 A EP 24846288A EP 4746884 A2 EP4746884 A2 EP 4746884A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutically acceptable
amine
isopropylpiperidin
quinolin
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24846288.9A
Other languages
German (de)
English (en)
Inventor
Jian Jin
Yan Xiong
Kwang-Su Park
Julia VELEZ
Jing Liu
Xian Chen
Juan SONG
Ling Xie
Ryan N. SHEEHY
Yonghui JIANG
Sung-Eun WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
University of North Carolina at Chapel Hill
Icahn School of Medicine at Mount Sinai
Original Assignee
Yale University
University of North Carolina at Chapel Hill
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, University of North Carolina at Chapel Hill, Icahn School of Medicine at Mount Sinai filed Critical Yale University
Publication of EP4746884A2 publication Critical patent/EP4746884A2/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une petite molécule N-(l-isopropylpipéridin-4-yl)-6-méthoxy-2-morpholino-7-(3-(pyrrolidin-l-yl)propoxy)quinolin-4-amine)) (MS 1262) qui inhibe les méthyltransférases G9a/GLP. Cet inhibiteur peut être utilisé dans le traitement de patients atteints de maladies associées à la G9a/GLP telles que la maladie d'Alzheimer et le syndrome de Prader-Willi.
EP24846288.9A 2023-07-21 2024-07-19 Inhibiteurs de la g9a/glp et méthodes d'utilisation Pending EP4746884A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363515010P 2023-07-21 2023-07-21
PCT/US2024/038842 WO2025024311A2 (fr) 2023-07-21 2024-07-19 Inhibiteurs de la g9a/glp et méthodes d'utilisation

Publications (1)

Publication Number Publication Date
EP4746884A2 true EP4746884A2 (fr) 2026-05-27

Family

ID=94375713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24846288.9A Pending EP4746884A2 (fr) 2023-07-21 2024-07-19 Inhibiteurs de la g9a/glp et méthodes d'utilisation

Country Status (3)

Country Link
EP (1) EP4746884A2 (fr)
JP (1) JP2026526826A (fr)
WO (1) WO2025024311A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033000A1 (en) * 2006-05-15 2008-02-07 Senex Biotechnology, Inc. Identification of CDKI pathway inhibitors
EP2777704A3 (fr) * 2007-06-01 2015-01-21 Wyeth LLC Traitement de leucémie résistant à l'imatinib en utilisant des 4-aminoquinoline-3-carbonitriles
US9567316B2 (en) * 2012-03-07 2017-02-14 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子

Also Published As

Publication number Publication date
WO2025024311A3 (fr) 2025-04-17
JP2026526826A (ja) 2026-08-10
WO2025024311A2 (fr) 2025-01-30

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260120

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR